Skip to main content

Table 6 Gradual decrease in the reimbursements for one applied Radium-223 dose from insurance companies (Dôvera, Všeobecná zdravotná poisťovňa, Union)

From: Application of the HTA Core Model for complex evaluation of the effectiveness and quality of Radium-223 treatment in patients with metastatic castration resistant prostate cancer

month of payment

Dôvera

Všeobecná zdravotná poisťovňa

Union

04/2015 – start of treatment

EUR 4369.54

EUR 5260.18

EUR 4734.17

01/2016

EUR 4734.17

06/2016

EUR 4471.00

11/2016

EUR 4369.54

05/2017

EUR 4267,92

EUR 4347.26

11/2017

EUR 3945.14

02/2018

EUR 4267.92

  1. Source: Own processing